Sanofi is to acquire Kiadis, a biotech specialising in therapies based around ‘off the shelf’ natural killer (NK) cells, for 308 million euros ($353 million).

© 2025 American City Business Journals. All rights reserved. Use of and/or registration on any portion of this site constitutes acceptance of our User Agreement ...

The Quebec, Canada-based biotech is using a different approach with its vaccine than the other candidates in clinical testing – 22 at last count according to the World Health Organisation – as ...

Tell your story, get noticed, and deliver results with Business Wire’s press release distribution services and investor relations solutions. Earn more coverage and increase your reach with the ...